Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
Stock Ideas
ETF Research Tools
ETF Center
ETF Screener
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Dividends
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Portfolio
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
More...
Plans
News
Smart Portfolio
Expert Center
Ideas
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed Tools
Try Now
Stock Ideas
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETFs
ETF Research Tools
ETF Center
ETF Screener
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Dividends
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto
Crypto Center
Bitcoin
Ethereum
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Portfolio
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Newsletters
Newsletter Center
News
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
More
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing
ANAB
Stock Latest News
Press Releases
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
16d ago
ANAB
Pre-Earnings
AnaptysBio (ANAB) Q1 Earnings Cheat Sheet
21d ago
ANAB
The Fly
AnaptysBio announces publication of data from Phase 2 GALLOP study
26d ago
ANAB
Press Releases
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
26d ago
ANAB
Press Releases
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
2M ago
ANAB
Press Releases
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial
2M ago
ANAB
The Fly
AnaptysBio ‘encouraged’ by GSK phase 3 trial results
2M ago
GSK
ANAB
Press Releases
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3M ago
ANAB
The Fly
AnaptysBio reports Q4 EPS (93c), consensus (96c)
3M ago
ANAB
Press Releases
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
3M ago
ANAB
Press Releases
AnaptysBio Announces Stock Repurchase Plan
4M ago
ANAB
The Fly
AnaptysBio board authorizes $50M stock repurchase plan
4M ago
ANAB
The Fly
AnaptysBio downgraded to Market Perform from Outperform at Raymond James
5M ago
ANAB
The Fly
AnaptysBio downgraded to Market Perform from Outperform at Raymond James
5M ago
ANAB
The Fly
AnaptysBio announces portfolio update, discloses $575M in cash to end 2022
5M ago
ANAB
Press Releases
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
5M ago
ANAB
Press Releases
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
6M ago
ANAB
The Fly
AnaptysBio, GSK announces Phase 3 RUBY trial results for JEMPERLI
6M ago
GSK
ANAB
Press Releases
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
6M ago
ANAB
Press Releases
AnaptysBio to Participate in Upcoming November Investor Conferences
7M ago
ANAB
Press Releases
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
8M ago
ANAB
Press Releases
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
9M ago
ANAB
Show More
You need to enable JavaScript to run this app.
